Regeneron Unveils Groundbreaking $200 Million Donation Matching Program to Expand Patient Access to Vision-Saving Treatments Regeneron Pharmaceuticals, a leader in biotechnology and a longtime advocate for equitable healthcare access, has…
Aetna Champions Industry-Wide Push to Streamline Prior Authorization and Improve Patient-Centered Health Care Experience Aetna, a CVS Health company, has publicly announced its strong support for a series of transformative…
Vertex and Ono Pharmaceutical Forge Strategic Partnership to Develop and Commercialize Povetacicept in Japan and South Korea In a move that underscores the growing international collaboration in advancing treatment for…
Amgen Unveils Full Phase 2 Data on Monthly Obesity Drug MariTide, Highlighting Robust Weight Loss and Cardiometabolic Benefits at ADA 2024 Amgen has presented comprehensive results from the first part…
Datroway Gains Accelerated FDA Approval for Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Datroway (datopotamab deruxtecan, also…
Merck’s WINREVAIR Achieves Primary Endpoint in Phase 3 HYPERION Trial for Pulmonary Arterial Hypertension in Newly Diagnosed Adults Merck, operating as MSD outside the United States and Canada, has announced…
Novo Nordisk Secures EU CHMP Backing for Ozempic® Label Expansion in PAD, Reinforcing Semaglutide’s Role in Managing Type 2 Diabetes with Comorbidities Novo Nordisk has announced that the European Medicines…
Exelixis Reports Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combo in Metastatic Colorectal Cancer Exelixis, has announced promising topline results from the STELLAR-303 phase 3 pivotal clinical trial, a…
Sarclisa Moves Closer to EU Approval for Frontline Treatment of Transplant-Eligible Multiple Myeloma Patients The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive…
Roche Unveils Promising Phase I/II Data for Next-Generation Bispecific Antibody NXT007 in Hemophilia A, Signaling a Major Step Toward Phase III Development Roche has shared encouraging new data from its…
Novo Nordisk’s CagriSema Delivers Up to 22.7% Weight Loss in Obese or Overweight Adults, REDEFINE 1 Trial Results Published in NEJM In a significant advancement for the treatment of obesity…
Novo Nordisk Unveils Positive Phase 3b Results for Mim8 in Hemophilia A: Seamless Switch from Emicizumab Shows Safety, Efficacy, and High Patient Satisfaction Novo Nordisk presented new findings from its…